Last reviewed · How we verify
FLUORESCEIN SODIUM
At a glance
| Generic name | FLUORESCEIN SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
Common side effects
- Stinging
- Burning
- Conjunctival redness
- Ocular hyperemia
- Eye irritation
- Blurred vision
- Punctate keratitis
Serious adverse events
- Corneal toxicity
- Corneal injury due to insensitivity
Key clinical trials
- A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer (NA)
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Automated Applanation Tonometry - Updated (NA)
- Retinal Vessel Leakage in Cerebral Small Vessel Disease
- Neoadjuvant Tebentafusp for Uveal Melanoma (PHASE2)
- Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children (NA)
- Intraoperative Use of I.V. Sodium Fluorescein in Suspected CNS Tumors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLUORESCEIN SODIUM CI brief — competitive landscape report
- FLUORESCEIN SODIUM updates RSS · CI watch RSS